U.S. commercial launch in thalassemia underway following December 2025 FDA approvalPre-sNDA meeting with FDA for mitapivat ...

Agios Pharmaceuticals (NASDAQ:AGIO) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline its ...

Biopharma companies—including AstraZeneca, BioNTech and Agios—peered farther into the future on the second day of JPM, ...

The average one-year price target for Agios Pharmaceuticals (NasdaqGS:AGIO) has been revised to $39.20 / share. This is an ...

Agios Pharmaceuticals (AGIO) announced its 2026 strategic priorities and key milestones anticipated during the year. Key ...

Agios Pharmaceuticals will sell its rights to the 15% royalty it holds on potential U.S. net sales of vorasidenib to Royalty Pharma. Royalty Pharma announced this week that it will pay Agios $905 ...

Agios Pharmaceuticals’ pivot from cancer to rare diseases culminated in the $1.8 billion sale of its oncology business. But the biotech still needs capital to support a product launch and additional ...

Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit and follow us on LinkedIn and X. Contacts: Investor Contact Morgan Sanford, Vice ...

After Agios' big pivot away from oncology back in 2020 and its first-in-class drug approval earlier this year, the drugmaker is gearing up for more changes. In a move unveiled Tuesday afternoon, Agios ...

– Safety Profile Consistent with Previously Published Phase 2 Data for Mitapivat in Patients with Pyruvate Kinase Deficiency – – Additional Data for the Phase 2 Study of Mitapivat in Thalassemia to be ...

Cambridge, Massachusetts-based Agios will market its new product, a twice-daily tablet, under the name “Pyrukynd.” The FDA’s Thursday approval covers use of the drug in adults who have an inherited ...